Analysts Anticipate ADMA Biologics Inc (ADMA) Will Announce Quarterly Sales of $6.68 Million

Equities analysts predict that ADMA Biologics Inc (NASDAQ:ADMA) will post $6.68 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for ADMA Biologics’ earnings. The lowest sales estimate is $5.50 million and the highest is $7.85 million. ADMA Biologics reported sales of $3.33 million during the same quarter last year, which indicates a positive year-over-year growth rate of 100.6%. The business is scheduled to issue its next earnings results on Friday, February 23rd.

On average, analysts expect that ADMA Biologics will report full year sales of $6.68 million for the current financial year, with estimates ranging from $16.30 million to $18.61 million. For the next fiscal year, analysts anticipate that the firm will report sales of $38.15 million per share, with estimates ranging from $28.31 million to $48.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover ADMA Biologics.

Several analysts recently commented on the stock. Raymond James Financial upgraded shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a report on Tuesday, November 14th. Maxim Group restated a “buy” rating and set a $8.00 price target (down from $13.00) on shares of ADMA Biologics in a report on Monday, December 11th.

Shares of ADMA Biologics (ADMA) opened at $3.71 on Monday. The company has a current ratio of 2.36, a quick ratio of 1.35 and a debt-to-equity ratio of 2.26. ADMA Biologics has a fifty-two week low of $2.01 and a fifty-two week high of $5.44.

An institutional investor recently raised its position in ADMA Biologics stock. Iguana Healthcare Management LLC increased its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 565,000 shares of the biotechnology company’s stock after purchasing an additional 415,000 shares during the quarter. Iguana Healthcare Management LLC owned approximately 2.19% of ADMA Biologics worth $1,740,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 32.78% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at

ADMA Biologics Company Profile

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with's FREE daily email newsletter.

Leave a Reply